Stiefel Laboratories Announces Expiration of Waiting Period to Acquire Barrier (BTRX)
More News related to BTRX
- FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
- Stiefel Laboratories Announces Expiration of Waiting Period to Acquire Barrier (BTRX)
- Cohen's SAC Capital Cuts Stake in Barrier Therapeutics (BTRX) to 1.21%
- Cohen's SAC Capital Discloses 8% Stake in Barrier Therapeutics (BTRX), Files 13D
- Notable Analyst Rating Changes 6/25: GD, NDAQ, JBL, BP Upgraded; BA, RPM, BTRX Downgraded
More News related to Mergers and Acquisitions
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Stiefel Laboratories, Inc. announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended has expired, for its proposed acquisition of Barrier Therapeutics, Inc. (Nasdaq: BTRX).
As previously announced, Stiefel Laboratories and Bengal Acquisition Inc., a direct wholly-owned subsidiary of Stiefel Laboratories, signed a definitive merger agreement with Barrier Therapeutics to acquire Barrier Therapeutics through a two-step transaction, a tender offer followed by a merger of Bengal Acquisition Inc. with and into Barrier Therapeutics. The transaction was approved by the board of directors of Barrier Therapeutics. [SM]
Related Categories
Mergers and AcquisitionsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
